Gold prices could see a mild relief rally if the Federal Reserve raises interest rates by 25 basis points as expected, removing uncertainty. However, if the Fed surprises by holding rates steady, gold could surge significantly, potentially reaching $5,000 per ounce, according to analyst Jesse Colombo. He noted that investors were overly bearish before the recent CPI report, causing a sell-off that was somewhat excessive. Colombo advises caution ahead of the Fed decision but is optimistic about gold's prospects, especially if the price closes solidly above the key $4,400 resistance level, signaling institutional support and a potential strong upward trend in the coming months.
Gold price outlook from Jesse Colombo is notable alongside Pluang's market data as of Sep 16, 2026 01:31 WIB. For readers following US stocks on Pluang, 48 of 150 priced stocks rose while 102 fell today. Notable movers include SNOW at USD 321.39 down 3.30%, GRAB at USD 2.92 down 3.15%, and LI at USD 11.80 down 3.04%.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
